NEW YORK (GenomeWeb) – Luminex said this week that double-digit growth in sales of its xTAG Respiratory Viral and Gastrointestinal Pathogen Panels contributed to an increase in first quarter revenues.

CEO Patrick Balthrop on an earnings call discussed the "solid performance" of the Austin, Texas-based company's assay business, which grew by 18 percent year over year, pushing the company's total Q1 revenues up 6 percent to $56.6 million compared to the first quarter of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.